Nintedanib (Ofev) prior authorization at CareFirst BCBS
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
CareFirst BCBS requires prior-authorization documentation for Nintedanib (Ofev): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
CareFirst BCBS reviews Nintedanib (Ofev) prior authorizations against its medical policy . CareFirst BCBS-specific context: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- CareFirst BCBS's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- DC/MD/VA cross-jurisdiction issues
- Step therapy on specialty drugs via CVS Caremark
- Behavioral health network adequacy
- BlueChoice HMO referral denials
Nintedanib (Ofev)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- FVC threshold requirements
- Indication restriction (IPF vs SSc-ILD vs PPF)
- GI tolerability not adequately documented
- LFT monitoring not documented
Brand: Ofev. Tyrosine kinase inhibitor (antifibrotic). FDA-approved for IPF, SSc-ILD (2019), and chronic fibrosing ILDs with progressive phenotype (PPF, 2020) — broader label than pirfenidone.
Manufacturer patient-assistance program: OFEV BI Cares Foundation — relevant when a CareFirst BCBS denial sticks and the patient needs bridge access while appealing.
How CareFirst BCBS approaches Antifibrotic agents PAs
For Nintedanib, check whether the current CareFirst BCBS Antifibrotic agents policy cites step therapy on specialty drugs via cvs caremark. Pharmacy-benefit review for Nintedanib at CareFirst BCBS is routed through CVS Caremark. The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with CareFirst BCBS; if denied, use the filing date and route printed on that denial notice. CareFirst BCBS's FVC-threshold restrictions are increasingly out of step with ATS/ERS/JRS/ALAT 2022 guidance, which recommends antifibrotic initiation regardless of FVC band. CareFirst BCBS is domiciled in MD, so unresolved appeals escalate to the MD insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://provider.carefirst.com) with the same packet plus an applicable, current clinical source supporting Nintedanib (Ofev)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a CareFirst BCBS denial on DenialHelp.
Contact CareFirst BCBS
- Provider portal: https://provider.carefirst.com
Frequently asked questions
What documentation does CareFirst BCBS need for Nintedanib (Ofev) prior auth?
CareFirst BCBS's typical PA packet for Nintedanib (Ofev): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at CareFirst BCBS?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for Nintedanib (Ofev) at CareFirst BCBS?
Preparation scenarios to check against the current notice and policy include: DC/MD/VA cross-jurisdiction issues; Step therapy on specialty drugs via CVS Caremark; Behavioral health network adequacy. These are not measured frequency claims. For Nintedanib (Ofev), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Does CareFirst BCBS's FVC threshold for Nintedanib match current ATS guidance?
Compare the current CareFirst BCBS antifibrotic policy with the current ATS/ERS/JRS/ALAT IPF guidance and the member's clinical record. If relevant, attach the HRCT report, multidisciplinary discussion, and specific FVC value with rate of decline; the treating clinician must verify the applicability of every source. Pharmacy-benefit handling is routed through CVS Caremark. External-review escalation for CareFirst BCBS fully-insured policies sits with the MD insurance department.
How do I prep for a peer-to-peer with CareFirst BCBS on Nintedanib (Ofev)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Nintedanib (Ofev) PA packet
Open ApprovalHelp — generate a Nintedanib (Ofev) prior-auth packet tailored to CareFirst BCBS's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com